Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the…
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, have announced a clinical development collaboration. The partnership will evaluate the investigational tyrosine kinase…
Transverse Medical, Inc., known for its POINT-GUARD™ Cerebral Embolic Protection device, is excited to announce the appointment of Ian T. Meredith, MD, to its Board of Directors. With over 35…
Melt Pharmaceuticals, Inc., a clinical-stage company focused on innovative procedural sedation solutions, has announced the dosing of the last patient in its pivotal Phase 3 study of MELT-300, a non-IV,…
MiLaboratories, a leader in computational biology innovation, is excited to announce the successful completion of its Series A funding round, led by Madrid-based Kfund, with additional support from Speedinvest and…
Siemens Healthineers is collaborating with over 20 industry and public partners, including seven leading stroke hospitals, to enhance stroke management across Europe. The five-year UMBRELLA project, with a total budget…
Elevance Health (NYSE: ELV) has announced its affiliated health plans will offer flexible Medicare Advantage options with personalized supplemental benefits aimed at enhancing the overall health of nearly 40.3 million…
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on innovative treatments for neurological diseases, announced the granting of inducement awards to three new employees. The Board’s Compensation Committee…
Kerecis, a leader in the use of fish skin and fatty acids for tissue regeneration, has announced the publication of significant study results in the New England Journal of Medicine…
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) with…
OS Therapies (NYSE American: OSTX) announced today that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) for OST-HER2 in recurrent, resected osteosarcoma has completed their final…
Fresenius Kabi, part of Fresenius and specializing in biopharmaceuticals, clinical nutrition, and medical technologies, along with Formycon AG, an independent developer of biosimilars, has announced FDA approval for Otulfi™ (ustekinumab-aauz),…